Forging Forward in Photodynamic Therapy
Authors:
- Gwendolyn M. CramerGCGwendolyn M. Cramer
- Keith A. CengelKCKeith A. Cengel
- Theresa M. BuschTheresa M. Busch
Open Access
- 15 February 2022
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (4) , 534-536
Abstract
In 1978, a Cancer Research article by Dougherty and colleagues reported the first large-scale clinical trial of photodynamic therapy (PDT) for treatment of 113 cutaneous or subcutaneous lesions associated with ten different kinds of malignancies. In classic applications, PDT depends on excitation of a tissue-localized photosensitizer with wavelengths of visible light to damage malignant or otherwise diseased tissues. Thus, in this landmark article, photosensitizer (hematoporphyrin derivative) dose, drug–light interval, and fractionation scheme were evaluated for their therapeutic efficacy and normal tissue damage. From their observations came early evidence of the mechanisms of PDT's antitumor action, and in the decades since this work, our knowledge of these mechanisms has grown to build an understanding of the multifaceted nature of PDT. These facets are comprised of multiple cell death pathways, together with antivascular and immune stimulatory actions that constitute a PDT reaction. Mechanism-informed PDT protocols support the contribution of PDT to multimodality treatment approaches. Moreover, guided by an understanding of its mechanisms, PDT can be applied to clinical needs in fields beyond oncology. Undoubtedly, there still remains more to learn; new modes of cell death continue to be elucidated with relevance to PDT, and factors that drive PDT innate and adaptive immune responses are not yet fully understood. As research continues to forge a path forward for PDT in the clinic, direction is provided by anchoring new applications in mechanistically grounded protocol design, as was first exemplified in the landmark work conducted by Dougherty and colleagues. See related article by Dougherty and colleagues, Cancer Res 1978;38:2628–35Keywords
Funding Information
- NIH (R01 CA236362, P01 CA087971)
This publication has 11 references indexed in Scilit:
- Recent advances in innovative strategies for enhanced cancer photodynamic therapyTheranostics, 2021
- Photodynamic therapy: apoptosis, paraptosis and beyondApoptosis, 2020
- Clinical development and potential of photothermal and photodynamic therapies for cancerNature Reviews Clinical Oncology, 2020
- Photodynamic Therapy and Immune Checkpoint Blockade†Photochemistry and Photobiology, 2020
- Blood Flow Measurements Enable Optimization of Light Delivery for Personalized Photodynamic TherapyCancers, 2020
- Preclinical and Clinical Evidence of Immune Responses Triggered in Oncologic Photodynamic Therapy: Clinical RecommendationsJournal of Clinical Medicine, 2020
- Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunityBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2019
- 5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomasJournal of Neuro-Oncology, 2019
- Beyond the Barriers of Light Penetration: Strategies, Perspectives and Possibilities for Photodynamic TherapyTheranostics, 2016
- Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary diseaseCancer Immunology, Immunotherapy, 2014